AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05052788 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine .
Study NCT05845281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivakain + deksametazon Adjuvant
Description: In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
Study NCT05845281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bupivakain + deksametazon Adjuvant
Description: In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
Study NCT05661422 — intervention group
Intervention type: DEVICE
Intervention: RESP™ Biosensor
Description: The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
Study NCT02054559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
Study NCT02054559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
Study NCT02054559 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT05650203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006
Description: 1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).
Study NCT05560620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
Study NCT05560620 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Deprivation
Description: Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
Study NCT05560620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
Study NCT05560620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
Study NCT05560620 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Caffeine
Description: De-caffeinated coffee
Study NCT04829071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit motor learning
Description: Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
Study NCT04829071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit motor learning
Description: Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
Study NCT06459700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplements
Description: See arm/group description
Study NCT06459700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplements
Description: See arm/group description
Study NCT06108011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lollipop
Description: sucking of lollipop after operation
Study NCT05194332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP sonication to the amygdala
Description: LIFUP sonication to amygdala will be performed.
Study NCT04739943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Monitoring
Description: Participants use a smartphone app for self monitoring of respiratory symptoms
Study NCT05362448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frequency
Description: First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
Study NCT05362448 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Frequency
Description: First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
Study NCT05162404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education Program
Description: The following topics are addressed in each module of the videos:~1. Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~2. Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~3. How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment.
Study NCT05969470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal fixation with short intramedullary nails
Description: Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a shorter intramedullary nail (defined as defined as less than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
Study NCT05969470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal fixation with long intramedullary nails
Description: Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a longer intramedullary nail (defined as greater than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
Study NCT05588284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioJet device
Description: A device can be used for thrombus aspiration and thrombolysis.
Study NCT05588284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: anticoagulation alone
Description: a medicine for anticoagulation therapy
Study NCT00992862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.
Study NCT00992862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Univasc® 15mg Tablets
Study NCT05775419 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (4 courses)
Description: Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
Study NCT05775419 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Concurrent chemotherapy (2 courses)
Description: Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;
Study NCT06183034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Very Low Calorie Diet
Description: Participants will receive a very low calorie diet as described in the arm/group
Study NCT05032014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M9
Description: one times a day during the whole treatment
Study NCT05032014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04249427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab Prefilled Syringe
Description: 140mg Erenumab, pre-filled syringe given by subcutaneous injection
Study NCT04249427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, pre-filled syringe given by subcutaneous injection
Study NCT04522219 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Description: Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
Study NCT05562869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept 250 Milligram Intravenous Powder for Solution
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Study NCT06319027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC-MRI
Study NCT06319027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT06319027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-Chelate
Description: Receive gadolinium-based contrast agent
Study NCT06319027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy
Description: Undergo MR spectroscopy
Study NCT04519866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Manual acupuncture (see procedures below) will be administered first to obtain the de qi sensation. After de qi is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min.~Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms.
Study NCT04519866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture
Description: After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness).~Acupoints used will be similar to those mentioned for electroacupuncture (see above).
Study NCT06319027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05350020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef 100 MG Injection
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
Study NCT05350020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100mg/ml
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
Study NCT06233604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
Study NCT06233604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
Study NCT06233604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
Study NCT04608773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Remineralizing Extreme Dry Mouth Spray with Xylitol
Description: oral hydrating spray
Study NCT04608773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alcohol-Free Moisturizing Dry Mouth Spray
Description: oral hydrating spray
Study NCT04812197 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen Collection(Punch Biopsy)
Description: Punch Biopsy of Skin
Study NCT05539144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Oropharyngeal mucosa
Description: Oropharyngeal mucosa was delineated as OARs and limiting its dose
Study NCT05539144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: oropharynx
Description: oropharynx was delineated as OARs and limiting its dose
Study NCT05539144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: oropharynx and oropharyngeal mucosa
Description: oropharynx and oropharyngeal mucosawere delineated as OARs and limiting its dose
Study NCT05930613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab (CIMZIA® ; TNF-α antagonist)
Description: 400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
Study NCT05930613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0.9 % solution)
Description: NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
Study NCT05562167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNO3
Description: 10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
Study NCT05562167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Study NCT06550089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
Study NCT06550089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
Study NCT04966845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of concentration on exhaled Carbon Monoxide
Description: exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]
Study NCT05570773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peer support program
Description: Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
Study NCT01315691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment.
Study NCT01315691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for liposomal amikacin for inhalation
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days.
Study NCT05447091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOH game- high dose
Description: Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
Study NCT06197360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on BCW Theory of Health Education
Description: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.
Study NCT06197360 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General diabetes health education
Description: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
Study NCT05447091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOH game- low dose
Description: Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
Study NCT05447091 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: LOH sham game
Description: Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
Study NCT05789368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: consume 1 sachet per day
Study NCT05789368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VeCollal sachet
Description: consume 1 sachet per day
Study NCT05789368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen sachet
Description: consume 1 sachet per day
Study NCT04865133 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04865133 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical record reviewed
Study NCT06251284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)